Turning the Page on Zohydro? New Formulations, New Division Leadership Should Help FDA Move Forward in Opioids
This article was originally published in The Pink Sheet Daily
Executive Summary
The long-time head of FDA’s pain drug review group, Bob Rappaport, has retired after 20 years at FDA. The new acting Division Director is Sharon Hertz – suggesting continuity in the substance of reviews, but perhaps a symbolic change in moving beyond the controversy over Zohydro.
You may also be interested in...
Zogenix Zohydro Launch Will Test FDA’s Balanced Approach On Opioid Pain Reviews
FDA approved Zogenix’ single-entity hydrocodone product following a negative advisory committee meeting, and is facing ongoing opposition as the drug’s launch begins. The agency argues the risk is consistent with other extended-release opioids – and abuse-deterrent technology is too new to require.
US FDA Punts To Congress On CBD: Rx Topics Remain Outside Political Spotlight
FDA is formally asking Congress to weigh in on the best approach to regulate CBD in consumer products. That provides another target for legislative attention that may mean that FDA’s core drug regulatory activities stay comfortably out of the spotlight.
The IRA And US FDA: How Will Agency View Any Drug Development Changes?
US biopharma companies are warning of significant changes in drug development priorities as they prepare for the implementation of new Medicare pricing measures enacted in 2022. Those changes will have ripple effects on the FDA, which may spark some responses.